C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy

C4 Therapeutics ( (CCCC) ) has provided an announcement.

On January 14, 2026, C4 Therapeutics outlined a multi-year strategy centered on advancing its lead IKZF1/3 degrader cemsidomide toward potential best-in-class status in multiple myeloma, alongside a refocused discovery effort on novel targets in validated inflammatory and neuro-inflammatory pathways. The company plans to start the Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone in the first quarter of 2026 using a 100 µg dose, initiate a Phase 1b study with elranatamab in the second quarter of 2026, and work toward pivotal data readouts and a potential U.S. new drug application in fourth-line or later multiple myeloma by year-end 2028, supported by Phase 1 data from 2025 showing overall response rates of 40% and 53% at the two highest dose levels. C4T also detailed a goal to begin a Phase 3 trial of cemsidomide in combination with a BCMA bispecific antibody by early 2028, use data from its CFT8919 program in China to guide ex-China development in 2026, and file up to three investigational new drug applications from its internal discovery pipeline by 2028. The company reported that its cash runway extends to the end of 2028, providing funding through several clinical and partnership milestones, including advancement of collaborations with Merck KGaA, Roche and Biogen, positioning C4T to strengthen its presence in targeted protein degradation and potentially enhance value for patients and investors if the planned trials and discovery initiatives succeed.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Spark’s Take on CCCC Stock

According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.

The score is driven primarily by weak financial performance (large ongoing losses and substantial cash burn), which outweighs the improved liquidity outlook from the recent financing. Technicals are mixed but generally soft (below key moving averages with negative MACD), and valuation is constrained by negative earnings and no dividend.

To see Spark’s full report on CCCC stock, click here.

More about C4 Therapeutics

C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, developing small-molecule degrader medicines primarily in oncology and expanding into inflammation, neuro-inflammation and neuro-degenerative diseases. Leveraging its TORPEDO platform, the company aims to address difficult-to-treat and previously undruggable targets by harnessing the body’s protein recycling system, with a market focus on multiple myeloma and other serious conditions with high unmet medical need.

Average Trading Volume: 1,797,605

Technical Sentiment Signal: Sell

Current Market Cap: $206.4M

See more insights into CCCC stock on TipRanks’ Stock Analysis page.